1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 62, n° 6
pages 1013-1030 (juin 2010)
Doi : 10.1016/j.jaad.2009.06.048

Efficacy and safety of treatments for childhood psoriasis: A systematic literature review

Michelle E.A. de Jager, MD , Elke M.G.J. de Jong, MD, PhD, Peter C.M. van de Kerkhof, MD, PhD, Marieke M.B. Seyger, MD, PhD
Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands 

Reprint requests: Michelle E. A. de Jager, MD, Department of Dermatology, 370, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

Evidence-based recommendations for therapeutic decision making in childhood psoriasis are lacking.


We sought to systematically review all available literature concerning treatment efficacy and safety in childhood psoriasis and to propose a recommendation for topical and systemic treatment of childhood psoriasis.


Databases searched were PubMed, EMBASE, and the Cochrane Controlled Clinical Trial Register. All studies reporting on efficacy and safety of all treatment options in childhood psoriasis were obtained and a level of evidence was determined.


Literature search revealed 2649 studies, of which 64 studies met the inclusion criteria. The majority of topical and systemic therapies given in childhood psoriasis are efficacious. Short-term side effects were usually mild; long-term side effects were not described.


Most conclusions formulated are not based on randomized controlled trials.


A rough summary of the proposed algorithm is as follows: first, calcipotriene with/without topical corticosteroids, followed by dithranol. Methotrexate is considered to be the systemic treatment of choice.

The full text of this article is available in PDF format.

Key words : childhood psoriasis, efficacy, safety, treatment

Abbreviations used : LOE, MTX, NB, PASI, PUVA, RCT, UV

 Supported by University Medical Center St Radboud Foundation, which received funding from Wyeth Pharmaceuticals for the project. Wyeth Pharmaceuticals played no role in the design and execution of the study or in data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval.
 Conflicts of interest: None declared.
 Disclosure: Dr de Jager participated in trials funded by Schering Plough and Abbott. Dr de Jong served as consultant for Biogen, Serono, Wyeth, and Abbott. She also received research grants from Merck Serono and Wyeth. Dr van de Kerkhof served as consultant for Schering Plough, Cellgene, Centocor, Allmirall, UCB, Wyeth, Pfizer, Soffinova, Abbott, Actelion, Galderma, Novartis, Janssen Cilag, and Leo Pharma. He also received research grants from Centocor, Wyeth, Schering Plough, Merck Serono, Abbott, and Philips Lighting. Dr Seyger has served as a consultant for Wyeth and participated in trials funded by Schering Plough and Wyeth.

© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline